Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.44 |
| ▸ | MDM4 | O15151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893983 | 0.91 | MDM2 (0.46) | MDM2MDM4TP53 | |
| SCHEMBL9894211 | 0.91 | MDM2 (0.55) | MDM2MDM4TP53 | |
| SCHEMBL9894076 | 0.89 | MDM2 (0.58) | MDM2MDM4MEN1KMT2AGABRA2 | |
| SCHEMBL1437376 | 0.89 | MDM2 (0.45) | MDM2MEN1KMT2AGABRA2GABRB2 | |
| SCHEMBL9893649 | 0.87 | MDM2 (0.52) | MDM2MDM4MEN1KMT2AGABRA2 | |
| SCHEMBL9893678 | 0.86 | MDM2 (0.62) | MDM2GABRA2GABRB2 | |
| SCHEMBL1438098 | 0.83 | MDM2 (0.62) | MDM2GABRA2GABRB2 | |
| SCHEMBL9894458 | 0.82 | MDM2 (0.54) | MDM2MDM4MEN1KMT2ATP53 | |
| SCHEMBL1437222 | 0.81 | TP53 (0.38) | MDM2MDM4TP53 | |
| SCHEMBL1437573 | 0.81 | MDM2 (0.41) | MDM2KMT2AGABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885MDM4 1/4885MEN1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.